hit counter
Biocept, Inc. (BIOC) Stock News Sentiment & Price - Sentifly
BIOC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Biocept, Inc. (BIOC)

USA
Medical Laboratories & Research
NASDAQ
BIOC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BIOC Latest news
Business Wire
Neutral
Biocept to Present at the LD Micro Main Event on October 13
2021-10-06 08:00

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #LD_Micro--Biocept to present at LD Micro Main Event

Benzinga
Positive
Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients
2021-09-29 13:28

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10% and 30% of cancer patients, and a much higher percentage of late-stage cancer patients will develop brain or spinal cord metastasis.

Proactive Investors
Positive
Biocept implements COVID-19 testing services at more than 30 community college campuses across California
2021-09-22 09:25

Biocept Inc has implemented its COVID-19 testing services at more than 30 community college campuses across California.  Also, the company said it is streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 testing.

Business Wire
Neutral
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
2021-09-22 08:17

SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.

InvestorPlace
Positive
7 of the Best Penny Stocks to Buy Coming Into Year-End
2021-09-21 13:40

These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared first on InvestorPlace.

Business Wire
Neutral
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
2021-09-21 08:17

SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.

Business Wire
Neutral
Biocept to Present at Four Virtual Investor Conferences in September
2021-09-07 08:00

SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m. Pacific time). Op

Business Wire
Neutral
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-31 20:00

SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees. These inducement stock options have a grant date of August 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement sto

Benzinga
Positive
Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
2021-08-19 11:37

Biocept Inc (NASDAQ:BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.

Proactive Investors
Neutral
Biocept says a study of its cerebrospinal fluid assay CNSide shows potential use for cancer treatment
2021-08-19 11:07

Biocept Inc told investors that its cerebrospinal fluid assay CNSide had been shown to be able to detect markers of a complication of non-small cell lung cancer (NSCLC), which could mean targeted treatment that would allow patients' lives to be extended. More than 198,000 people are diagnosed with NSCLC each year, said Biocept, and an estimated 3-9% of those will develop leptomeningeal carcinomatosis (LMC), where the cancer spreads to the membranes surrounding the brain and spinal cord.

Loading more news...